FetchDog
$RNAC If their clinical trials continue meeting objectives (I think very likely), their peak annual sales from Descartes-08 (according to Gemini AI):
Peak annual US revenue estimates for Descartes-08 (Gemini AI)
AChR+ gMG : $450 million to $650 million
Myositis : $350 million to $450 million
JDM : $150 million to $250 million
For Descartes-08 revenue, I'm guessing their market cap multiplier realtive to sales will be a modest 4x due to high costs of goods and sales/marketing. I could be way off on this.
The biggest upside potential may come from their "In Vivo CAR-T Platform" (WestGene LNP platform with Cartesian’s mRNA payload). Initial phase-1 ata for this platform in 2027-H1.
2

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault29.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault13.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault16.jpg)